

**24 February 2026**

ASX Market Announcements Office  
ASX Compliance Pty Ltd  
Level 40, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

Dear Sir/Madam,

**NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)**

Botanix Pharmaceuticals Limited (ASX: BOT, **Botanix** or **the Company**) advises that it has today completed tranche 1 of the placement targeting to raise a total of A\$40 million (before costs), as announced to ASX on 17 February 2026 (**Placement**). Tranche 1 of the Placement consisted of raising approximately A\$14.9 million (before costs) through the issue of 247,994,473 new fully paid ordinary shares in Botanix (**New Shares**) at A\$0.06 per New Share to institutional and sophisticated investors.

The remainder of the capital raising announced on 17 February 2026 is subject to the approval of shareholders at a general meeting of shareholders expected to be held in early April 2026.

The Company hereby provides notification under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) of the issue of the New Shares. The Corporations Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Corporations Act. By the Company giving this notice (**Notice**), a sale of the New Shares will fall within the exemption in section 708A(5) of the Corporations Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Corporations Act, the Company gives notice that:

- (a) the Company issued 247,994,473 New Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this Notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this Notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this Notice, there is no excluded information, within the meanings of section 708A(7) and 708A(8) of the Corporations Act.

Release authorised by the Board of Directors.



**Vince Ippolito**  
Executive Chairman

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra*<sup>™</sup> for the treatment of primary axillary hyperhidrosis. *Sofdra*<sup>™</sup> is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

#### General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

#### Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

#### Media enquiries

Haley Chartres

HACK

P: +61 423 139 163

[haley@hck.digital](mailto:haley@hck.digital)

## **Sofdra® Important Safety Information & Indication**

### **Indication**

*Sofdra* (sofpironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

### **IMPORTANT SAFETY INFORMATION**

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

### **Who should not use *Sofdra*?**

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

### **What should I tell my healthcare provider before using *Sofdra*?**

- **Tell your healthcare provider about all of your medical conditions**, including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, especially any anticholinergic medicines.

### **What are possible side effects of *Sofdra*?**

#### **Serious side effects may include:**

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

**The most common side effects** of *Sofdra* include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

**Keep *Sofdra* and all medicines out of the reach of children.**